Progresses Made in Series of Studies of Prevention and Control of COVID-19 with Lianhua Qingwen Capsules

SHIJIAZHUANG, China, March 21, 2022 /PRNewswire/ — On March 19, the Media Briefing on Prevention and Control of COVID-19 with Lianhua Qingwen Capsules, a patented Chinese medicine developed and produced by Yiling Pharmaceutical, was convened in Shijiazhuang City, Hebei Province, at which the in vitro experimental results of Lianhua Qingwen Capsules against SARS-CoV-2 Omicron variant by Guangzhou Institute of Respiratory Health recently were published. These experimental results show that Lianhua Qingwen Capsules have significant inhibiting effect on the cytopathic effect induced by Omicron variant so as to achieve the anti-novel coronavirus effect.